The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of modulation of sorafenib (SOR)-induced autophagy using hydroxychloroquine (HCQ) in advanced hepatocellular cancer (HCC).
 
Sukeshi Arora
Honoraria - Targeted Oncology
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Exelixis; Seagen
Speakers' Bureau - AstraZeneca; Bristol-Meyers Squibb; Seagen
Travel, Accommodations, Expenses - DAVA Oncology
 
Jennifer Moseley
No Relationships to Disclose
 
Luisa Arellano
No Relationships to Disclose
 
Mary Salazar
No Relationships to Disclose
 
Brittany Altermatt
No Relationships to Disclose
 
Lorena Fuentes
No Relationships to Disclose
 
Vincent Pham
No Relationships to Disclose
 
Gang Huang
No Relationships to Disclose
 
LuZhe Sun
No Relationships to Disclose
 
Joel Michalek
No Relationships to Disclose
 
Devalingam Mahalingam
Consulting or Advisory Role - Amgen; OncoOne; Qurient
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech
Research Funding - Amgen; Merck KGaA; Oncolytics